Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Qiming Medical-B (02500.HK) by 2,500 shares on November 21, 2025, marking a continuous trend of reduction over the past trading days [1] - Over the last 5 trading days, southbound funds have cumulatively reduced their holdings by 47,500 shares, while in the last 20 trading days, the total reduction amounts to 666,000 shares [1] - As of now, southbound funds hold 53,424,100 shares of Qiming Medical-B, which represents 12.11% of the company's total issued ordinary shares [1] Group 2 - Qiming Medical is primarily engaged in the research, production, and sales of biological heart valves, focusing on minimally invasive medical devices and auxiliary instruments for treating heart valve diseases [2] - The company's product line includes devices for treating various heart valve diseases, such as aortic valve, pulmonary valve, mitral valve, and tricuspid valve interventions, as well as systems for radiofrequency ablation and renal artery ultrasound ablation [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 embolic protection device [2]
启明医疗-B（02500.HK）：11月21日南向资金减持2500股